Natural Compounds Targeting Thymic Stromal Lymphopoietin (TSLP): A Promising Therapeutic Strategy for Atopic Dermatitis

Muhammad Suleman, Chiara Moltrasio, Paola Maura Tricarico, Angelo Valerio Marzano, Sergio Crovella · 2024

Read Natural Compounds Targeting Thymic Stromal Lymphopoietin (TSLP): A Promising Therapeutic Strategy for Atopic Dermatitis by Muhammad Suleman, Chiara Moltrasio, Paola Maura Tricarico, Angelo Valerio Marzano, Sergio Crovella (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11673240.txt.

Introduction

Muhammad Suleman and co-authors hunt, in a 2024 study, through a database of African natural products for compounds that can block a protein driving eczema. The protein, called TSLP, sits high in the chain of signals that sets off the allergic inflammation of atopic dermatitis. Blocking it is a proven strategy, and natural products offer a wide field of candidate shapes.

The team screened the database by computer, docking each compound against the protein's structure, then ran motion simulations on the best fits. Four compounds scored highest, gripping the protein tightly in the docking and the follow-up energy estimates. One pairing stayed the steadiest across the simulation. The compounds also showed favorable profiles for how a drug should travel and clear in the body. The authors offer the four as starting points for a gentler eczema treatment, pending lab tests.

Catalog record

CREATORMuhammad Suleman, Chiara Moltrasio, Paola Maura Tricarico, Angelo Valerio Marzano, Sergio Crovella
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11673240

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Natural Compounds Targeting Thymic Stromal Lymphopoietin (TSLP): A Promising Therapeutic Strategy for Atopic Dermatitis Authors: Muhammad Suleman, Chiara Moltrasio, Paola Maura Tricarico, Angelo Valerio Marzano, Sergio Crovella Published: 2024 ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease with rising prevalence, marked by eczematous lesions, itching, and a weakened skin barrier often tied to filaggrin gene mutations. This breakdown allows allergen and microbe entry, with thymic stromal lymphopoietin (TSLP) playing a crucial role by activating immune pathways that amplify the allergic response. TSLP’s central role in AD pathogenesis makes it a promising therapeutic target. Consequently, in this study, we used the virtual drug screening, molecular dynamics simulation, and binding free energies calculation approaches to explore the African Natural Product Database against the TSLP protein. The molecular screening identified four compounds with high docking scores, namely SA_0090 (−7.37), EA_0131 (−7.10), NA_0018 (−7.03), and WA_0006 (−6.99 kcal/mol). Furthermore, the KD analysis showed a strong binding affinity of these compounds with TSLP, with values of −5.36, −5.36, −5.34, and −5.32 kcal/mol, respectively. Moreover, the strong binding affinity of these compounds was further validated by molecular dynamic simulation analysis, which revealed that the WA_0006-TSLP is the most stable complex with the lowest average RMSD. However, the total binding free energies were −40.5602, −41.0967, −27.3293, and −51.3496 kcal/mol, respectively, showing the strong interaction between the selected compounds and TSLP. Likewise, these compounds showed excellent pharmacokinetics characteristics. In conclusion, this integrative approach provides a foundation for the development of safe and effective treatments for AD, potentially offering relief to millions of patients worldwide. 1. Introduction Atopic dermatitis (AD) is a common chronic inflammatory skin condition characterized by eczematous lesions, intense itching, and xerosis, significantly affecting the quality of life of millions worldwide. AD’s prevalence has risen dramatically in recent decades, particularly in industrialized nations, and its pathogenesis is complex, involving both genetic and environmental factors. A key feature of AD is the breakdown of the epidermal barrier, often linked to mutations in the filaggrin gene, which facilitates the penetration of allergens and microbes into the skin [1]. This results in an abnormal immune response dominated by T helper type 2 (Th2) cells, which produce interleukins that further exacerbate the inflammation [2]. Thymic stromal lymphopoietin (TSLP), a cytokine produced primarily by epithelial cells, has emerged as a critical player in this process. TSLP is highly expressed in the lesional skin of AD patients and acts by activating dendritic cells, which then promote the differentiation of naive T cells into Th2 cells, amplifying the allergic response [3]. Furthermore, TSLP influences the activity of other immune cells, such as basophils, eosinophils, and innate lymphoid cells, all of which contribute to the chronic inflammation characteristic of AD [4]. Given the central role of TSLP in the pathogenesis of AD, it has become a key target for therapeutic interventions. Indeed, therapies that block TSLP signaling, such as biologics, have shown promise in reducing AD symptoms [5]. However, these treatments can be costly and may have long-term side effects, highlighting the need for safer, more accessible alternatives [6]. In this context, natural compounds have gained increasing attention due to their broad range of bioactive properties, low toxicity, and potential to modulate key pathways involved in AD, including TSLP signaling [7]. Several natural compounds, such as quercetin, curcumin, epigallocatechin gallate (EGCG), licorice (Glycyrrhiza glabra), resveratrol, and Centella asiatica, have been shown to regulate the expression of TSLP and other pro-inflammatory mediators [8,9]. Quercetin, a flavonoid found in many fruits and vegetables, has been reported to inhibit TSLP secretion in keratinocytes, thereby reducing the activation of dendritic cells and the downstream Th2 response [10]. Similarly, curcumin, the active compound in turmeric, has demonstrated the ability to suppress TSLP expression in various inflammatory models, including AD, by modulating nuclear factor kappa B (NF-κB) signaling [11]. EGCG, the major catechin in green tea, has been shown to reduce TSLP levels in allergic skin inflammation models and inhibit the activation of dendritic cells [12]. Licorice root extract, particularly its active component glycyrrhizin, has long been used in traditional medicine for its anti-inflammatory properties and has recently been found to downregulate TSLP expression in keratinocytes, making it a potential candidate for AD treatment [13]. Resveratrol, a polyphenol found in grapes and berries, has also been shown to inhibit TSLP production and attenuate Th2-mediated inflammation in AD models [14]. Centella asiatica, commonly known as Gotu Kola, is a traditional medicinal herb that has demonstrated significant anti-inflammatory effects, including the inhibition of TSLP production in human keratinocytes [15]. These natural compounds not only reduce TSLP expression but also target other aspects of the immune response, providing a multifaceted approach to AD management. Despite the promising results from preclinical studies, further research is needed to validate the clinical efficacy of these natural compounds and determine optimal formulations and dosages for AD treatment. Moreover, the potential for synergistic effects between these compounds and existing therapies, such as corticosteroids and biologics, warrants exploration. As the demand for more natural and holistic approaches to treating chronic diseases like AD grows, the development of TSLP-targeted therapies using natural compounds offers a promising avenue for future research and clinical practice. This study demonstrates the potential of using of virtual drug screening and molecular dynamics simulations to reposition natural compounds for the treatment of atopic dermatitis. In this study, the African natural compounds were screened against TSLP, and strong binding affinity of the selected compounds was further verified by using the molecular dynamics simulation and binding free calculation approaches. The integrative approach adopted herein not only enhances our understanding of the molecular interactions involved but also provides a foundation for the development of safer and more effective treatments for AD, potentially offering relief to millions of patients worldwide. 2. Materials and Methods 2.1. Crystal Structure Retrieval and Preparation The crystal structure of the TSLP complex (PDB ID: 5J12) was sourced from the Protein Data Bank (RCSB PDB) [16] (https://www.rcsb.org/structure/5nt1) (accessed on 7 August 2024). PyMOL was then used to remove any water molecules from the structure [17]. Hydrogen atoms were added, and structural minimization was performed on the protein using Chimera [18,19]. 2.2. Molecular Screening of Natural Product Libraries This study utilized the African Natural Product Database, containing diverse African medicinal compounds, and screened them for drug-likeness and toxicity using the FAF4drug webserver, filtering out compounds that violated Lipinski’s rule of five [19]. Ligands were prepared by converting them to the pdbqt format, with tools like Open Babel assigning charges and atom types; the ligand preparation process included considering non-polar hydrogen atoms, Gasteiger charges, and defining torsion tree roots for flexibility analysis, while receptors were prepared using AutoGrid to define the docking space. The virtual screening was performed with EasyDock Vina 2.0, starting with an initial low-exhaustiveness screening (set to 16) for efficiency, followed by a more rigorous re-screening (exhaustiveness of 64) for top hits to reduce false positives. Then, the top 10% of high-ranking compounds underwent induced-fit docking (IFD) with AutoDockFR, accommodating receptor flexibility and enabling covalent docking using default parameters [20]. AutoDockFR generally utilizes force fields like AMBER or CHARMM, molecular dynamics (MD) simulation protocols, and scoring functions such as AMBER scoring or force-field-based scoring for induced-fit docking (IFD) simulations. Finally, on the basis

Read the complete text